Mineralys Therapeutics Files 8-K

Ticker: MLYS · Form: 8-K · Filed: May 22, 2025 · CIK: 1933414

Sentiment: neutral

Topics: corporate-governance, financial-reporting

TL;DR

Mineralys filed an 8-K on 5/22/25 for shareholder votes and financials.

AI Summary

Mineralys Therapeutics, Inc. filed an 8-K on May 22, 2025, reporting the submission of matters to a vote of security holders and financial statements and exhibits. The company, incorporated in Delaware, has its principal executive offices in Radnor, Pennsylvania.

Why It Matters

This filing indicates routine corporate actions and financial reporting, providing transparency to investors about the company's governance and financial status.

Risk Assessment

Risk Level: low — This is a routine filing for corporate actions and financial reporting, not indicating any immediate material changes or risks.

Key Numbers

Key Players & Entities

FAQ

What specific matters were submitted to a vote of security holders?

The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in this excerpt.

What financial statements and exhibits are being filed?

The filing lists 'Financial Statements and Exhibits' as an item, but the specific content of these statements and exhibits is not detailed in this excerpt.

When was Mineralys Therapeutics, Inc. incorporated?

Mineralys Therapeutics, Inc. was incorporated in Delaware, as stated in the filing.

What is the company's principal business address?

The company's principal executive offices are located at 150 N. Radnor Chester Road, Suite F200, Radnor, Pennsylvania 19087.

What is the company's telephone number?

The registrant's telephone number is (888) 378-6240.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 22, 2025 regarding Mineralys Therapeutics, Inc. (MLYS).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing